ExpreS2ion Biotech Holding
2.72 SEK +6.67%HC Andersen Capital receives payment from ExpreS2ion Biotech Holding for a DigitalIR/Corporate Visibility agreement. See disclaimer.
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Read moreAnalyst
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Saxo Bank A/S Client Assets | 9.2 % | 9.2 % |
BNY Mellon SA/NV for Jyske Ban | 5.6 % | 5.6 % |
Premium
This content is for our Premium customers only.
Forum updates
Dagens aktienyheder 17/04: Gubra Netcompany, Scandinavian Medical Solutions, ExpreS2ion Biotechnologies og Curasight
Expres2ion Biotechnologies: Completes GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate
Join Inderes community
Don't miss out - create an account and get all the possible benefits